186 related articles for article (PubMed ID: 18666038)
1. Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
Ripamonti D; Maggiolo F
Curr Opin Investig Drugs; 2008 Aug; 9(8):899-912. PubMed ID: 18666038
[TBL] [Abstract][Full Text] [Related]
2. [RILPIVIRINE -- a novel HIV-1 non-nucleoside reverse transcriptase inhibitor].
Snopková S; Havlíčková K; Polák P; Šlesinger P; Husa P
Klin Mikrobiol Infekc Lek; 2013 Mar; 19(1):19-22. PubMed ID: 23945833
[TBL] [Abstract][Full Text] [Related]
3. Rilpivirine (Edurant)--a new drug for HIV infection.
Med Lett Drugs Ther; 2011 Aug; 53(1371):67-8. PubMed ID: 21860365
[No Abstract] [Full Text] [Related]
4. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.
Crauwels H; van Heeswijk RP; Stevens M; Buelens A; Vanveggel S; Boven K; Hoetelmans R
AIDS Rev; 2013; 15(2):87-101. PubMed ID: 23681436
[TBL] [Abstract][Full Text] [Related]
5. Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor.
Garvey L; Winston A
Expert Opin Investig Drugs; 2009 Jul; 18(7):1035-41. PubMed ID: 19548857
[TBL] [Abstract][Full Text] [Related]
6. [Mechanism of action and pharmacokinetics of rilpivirine].
Portilla J; Estrada V
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():2-5. PubMed ID: 24252527
[TBL] [Abstract][Full Text] [Related]
7. Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor.
Ripamonti D; Bombana E; Rizzi M
Expert Rev Anti Infect Ther; 2014 Jan; 12(1):13-29. PubMed ID: 24308712
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects.
Crauwels H; Vingerhoets J; Ryan R; Witek J; Anderson D
Antivir Ther; 2012; 17(3):439-46. PubMed ID: 22293086
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalent formulation for the fixed-dose regimen of Truvada and TMC278 finalized.
AIDS Patient Care STDS; 2010 Jun; 24(6):395-6. PubMed ID: 20575158
[No Abstract] [Full Text] [Related]
10. [Conclusions. Position of rilpivirine in the management of infection by the human immunodeficiency virus].
Podzamczer D
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():44. PubMed ID: 24252533
[No Abstract] [Full Text] [Related]
11. Rilpivirine. First-line treatment of HIV infection: efavirenz is better documented.
Prescrire Int; 2012 Nov; 21(132):262-5. PubMed ID: 23210255
[TBL] [Abstract][Full Text] [Related]
12. Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor.
James C; Preininger L; Sweet M
Am J Health Syst Pharm; 2012 May; 69(10):857-61. PubMed ID: 22555080
[TBL] [Abstract][Full Text] [Related]
13. Researcher presents vexing information on rilpivirine.
Dalton P
Proj Inf Perspect; 2008 Sep; (46):10-2. PubMed ID: 19048650
[No Abstract] [Full Text] [Related]
14. Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection.
Fernández-Montero JV; Vispo E; Anta L; de Mendoza C; Soriano V
Expert Opin Pharmacother; 2012 May; 13(7):1007-14. PubMed ID: 22519768
[TBL] [Abstract][Full Text] [Related]
15. [Introduction. Rilpivirine].
Podzamczer D
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():1. PubMed ID: 24252526
[No Abstract] [Full Text] [Related]
16. Rilpivirine: a step forward in tailored HIV treatment.
Schrijvers R; Desimmie BA; Debyser Z
Lancet; 2011 Jul; 378(9787):201-3. PubMed ID: 21763920
[No Abstract] [Full Text] [Related]
17. Impact of food and different meal types on the pharmacokinetics of rilpivirine.
Crauwels HM; van Heeswijk RP; Buelens A; Stevens M; Boven K; Hoetelmans RM
J Clin Pharmacol; 2013 Aug; 53(8):834-40. PubMed ID: 23720136
[TBL] [Abstract][Full Text] [Related]
18. Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor.
Sharma M; Saravolatz LD
J Antimicrob Chemother; 2013 Feb; 68(2):250-6. PubMed ID: 23099850
[TBL] [Abstract][Full Text] [Related]
19. Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.
Schafer JJ; Short WR
Antivir Ther; 2012; 17(8):1495-502. PubMed ID: 22878339
[TBL] [Abstract][Full Text] [Related]
20. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.
Baert L; van 't Klooster G; Dries W; François M; Wouters A; Basstanie E; Iterbeke K; Stappers F; Stevens P; Schueller L; Van Remoortere P; Kraus G; Wigerinck P; Rosier J
Eur J Pharm Biopharm; 2009 Aug; 72(3):502-8. PubMed ID: 19328850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
